The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

Eli Lilly & Co. is bouncing back after a turbulent period, riding out volatility and posting a strong revenue increase in Q1 ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

In its first-quarter 2025 investor letter, Macquarie Large Cap Growth Fund highlighted stocks such as Eli Lilly and Company ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

For the time being, markets seem to be taking the U.S. attack on Iran as a blip. Whether that holds as the conflict goes on ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...